Business Of Biotech

On this episode, Mark Kotter, CEO of Bit.bio, discusses the concept of programmable biology and the challenges involved in building capabilities. They delve into the interdisciplinary team required, the innovative cell reprogramming at Bit.bio, focusing on regenerative medicine indications, funding journey, stem cell reprogramming for aging interventions, and visibility in the biotech space.

We love to hear from our listeners. Send us a message. Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iteration of a new technology is ever the best iteration of that technology. On this week's episode of the Business of Biotech, we welcome Carsten Rudolph, Ph.D., co-founder and CEO of a company that recognizes this room for improvement. Ethris is developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines.   Dr. Rudolph explains the concept, the business case, and how he's navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Renowned biotech CFO, Allan Shaw, shares the reasons behind cautious optimism for biotech's return, including December's M&A activity, interest rate reductions, and easing inflation. They also discuss the election year wildcard and the potential benefits of a metered biotech comeback. The podcast explores topics such as the impact of AI and ML in biotech, the evolution and significance of the JP Morgan conference, and the current state of the industry and innovations.

In this podcast, Dr. Jim Lee, head of Inflammation and Autoimmunity at Incyte, discusses the company's multimodal approach to R&D. They explore the impact of a multimodal approach in drug development, specifically in dermatology. They also discuss the connection between inflammation, oncology, and dermatology, as well as their advancements in dermatology and future plans. Additionally, they touch on the role of biologics in dermatology and the impact of having a celebrity spokesperson for patient awareness. Dr. Lee concludes by discussing upcoming milestones in R&D.

Dr. John Leonard, longtime CEO at Intellia Therapeutics, discusses the foundational elements of building a biotech hub, the influence of the AIDS epidemic on his career, the importance of experience and knowledge in scientific research, and Intellia's long-term DNA editing strategy. He also provides updates on the company's clinical pipeline and future plans.

In this episode, the relatively new CEO of Elevation Oncology, Joseph Ferra, discusses the significant changes he has made at the company. These changes include transitioning from a monoclonal antibody candidate to a phase 1 Claudin18.2 target in the ADC space. The podcast also explores the importance of technology and being a platform company in the biotech industry, as well as the expansion of a clinical trial for gastric cancer treatment. Ferra emphasizes the need for planning and adaptability in the biotech industry to make the right decisions.

We love to hear from our listeners. Send us a message. A new year marks a fresh start for biotech partnerships, and to kick off 2024, we're highlighting a good one. Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. On today's episode of the Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. In addition to contracts and master service agreements, the pair walk us through the day-to-day execution of the partnership and responsibilities of those involved in it. If you're considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you won't want to miss this episode. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

We love to hear from our listeners. Send us a message. Merry Christmas, Business of Biotechers! On this Christmas Day release, we’re taking a trip to the land down under to visit with Dr. Sam Costello, a former gastroenterologist-turned managing director and co-founder at Adelaide, Australia-based BiomeBank. We covered some ground on this one, most notably the unique path BiomeBank took to chalking up the first donor-derived microbiome therapeutic approval of its kind, anywhere in the world.  In a segment of biotech that’s been particularly battered of late, that’s a big, big win. We also talked about what’s behind Australia’s foray onto the global biotech scene, the public/private partnerships supporting that growth, why U.S. biotechs, in particular, are flocking there to conduct clinical trials, and whether Foster’s is really Australian for beer. Don’t miss it!Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Dr. Neela Patel and Dr. John Mulligan discuss Bonum Therapeutics' transition from Good Therapeutics, the Roche acquisition, challenges faced by early-stage biotech companies, and creating a better path for women in biotech.

We love to hear from our listeners. Send us a message. During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administraion, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than  25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way. But, it wasn't all glamor and heroics. Dybul had to influence some decidedly conservative global political machines of the importance of addressing the AIDS epidemic, particularly, at the time, in Africa. He had to fight through federal and global beuracracies for every dime of funding earned. His leadership required resolve in the face of complexity and adversity. Nothing could have better prepared him for biotech leadership, which has dealt Dr. Dybul an unfair share of unique adversity that's, quite frankly, the stuff of a Dateline NBC episode. On this epsiode of the Business of Biotech podcast, Dybul, CEO at Renovaro Biosciences, gets introspective on leadership forged in the fires of public service and battle-tested in the private sector.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/